Provenge Poised For Broad Insurance Coverage, Despite Grumbles On Price
Executive Summary
After a strong endorsement in the National Comprehensive Cancer Network guidelines, Dendreon's first-of-its-kind prostate cancer vaccine Provenge appears well positioned for broad insurance coverage and take-up with physicians
You may also be interested in...
Under Sanpower, Can Provenge Finally Have A Happy Ending?
Strategy of focusing immunotherapy on urologists and earlier stage prostate cancer is paying off, says CEO James Caggiano, as Dendreon becomes a standalone company under Chinese conglomerate Sanpower
Pfizer’s Xalkori Joins The Six-Figure Oncology Drug Club
The roll-out of Pfizer Inc.’s new personalized non-small cell lung cancer therapy Xalkori blends right in with the prevailing trends in cancer drug launches, proving that six-figure pricing now seems to be the new black in oncology.
Pfizer’s Xalkori Joins The Six-Figure Oncology Drug Club
The roll-out of Pfizer Inc.’s new personalized non-small cell lung cancer therapy Xalkori blends right in with the prevailing trends in cancer drug launches, proving that six-figure pricing now seems to be the new black in oncology.